Skip to Content
Merck
  • Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer.

Cell reports (2020-12-31)
Taekyoung Kwak, Fang Wang, Hui Deng, Thomas Condamine, Vinit Kumar, Michela Perego, Andrew Kossenkov, Luis J Montaner, Xiaowei Xu, Wei Xu, Cathy Zheng, Lynn M Schuchter, Ravi K Amaravadi, Tara C Mitchell, Giorgos C Karakousis, Charles Mulligan, Brian Nam, Gregory Masters, Neil Hockstein, Joseph Bennett, Yulia Nefedova, Dmitry I Gabrilovich
ABSTRACT

Here, we report that functional heterogeneity of macrophages in cancer could be determined by the nature of their precursors: monocytes (Mons) and monocytic myeloid-derived suppressor cells (M-MDSCs). Macrophages that are differentiated from M-MDSCs, but not from Mons, are immune suppressive, with a genomic profile matching that of M-MDSCs. Immune-suppressive activity of M-MDSC-derived macrophages is dependent on the persistent expression of S100A9 protein in these cells. S100A9 also promotes M2 polarization of macrophages. Tissue-resident- and Mon-derived macrophages lack expression of this protein. S100A9-dependent immune-suppressive activity of macrophages involves transcription factor C/EBPβ. The presence of S100A9-positive macrophages in tumor tissues is associated with shorter survival in patients with head and neck cancer and poor response to PD-1 antibody treatment in patients with metastatic melanoma. Thus, this study reveals the pathway of the development of immune-suppressive macrophages and suggests an approach to their selective targeting.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipopolysaccharides from Escherichia coli K-235, purified by gel-filtration chromatography
Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
RIPA Buffer